The U.S. Food and Drug Administration has approved Genentech's combination regimen of Venclexta (venetoclax) plus acalabrutinib for treating previously untreated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE